EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19, European Medicines Agency

The decision to start the rolling review was based on preliminary results from an ongoing study evaluating it in the treatment of non-hospitalised patients with Covid-19. The review will continue until enough evidence is available to support a marketing authorisation application. 7 May.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news